Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC).

Jeffrey Goh, Jermaine Coward, Bo Gao, Ines P. da Silva, Mark Voskoboynik, Daphne Day, Amy L. Body, Hui K. Gan, Cheng Chen, Xiao Xiang, Cong Fei, Liu Yang, Michael Millward

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

Original languageEnglish
Number of pages2
JournalCancer Research
Issue number13
Publication statusPublished - Jul 2021

Cite this